<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108077</url>
  </required_header>
  <id_info>
    <org_study_id>IBCE_CIK</org_study_id>
    <nct_id>NCT05108077</nct_id>
  </id_info>
  <brief_title>Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells</brief_title>
  <official_title>Treatment of Metastatic Tumors of the Urogenital Area (Bladder Cancer, Renal Cancel) With Cytokine-induced Killer Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belarusian State Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical efficacy evaluation as measured by 1 year relapse free survival</measure>
    <time_frame>1 year</time_frame>
    <description>The 1 year relapse free survival will be used as a measure for the clinical efficacy of the cytokine-induced killer cells in the treatment of malignant tumors of urogenital area</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and treatment tolerance of the cytokine-induced killer cells</measure>
    <time_frame>1 year</time_frame>
    <description>Safety of the cytokine-induced killer cells application, which include determination of adverse effects associated with the therapy. Blood tests, renal and liver function will be studied.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Renal Cancer</condition>
  <arm_group>
    <arm_group_label>Cytokine-induced killer cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with the metastatic tumors of the urogenital area receiving standard treatment and autologous cytokine-induced killer cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with metastatic tumors of the urogenital area receiving standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cytokine-induced killer cells</intervention_name>
    <description>Autologous cytokine-induced killer cells injected intravenously</description>
    <arm_group_label>Cytokine-induced killer cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard treatment according to the Clinical protocols</intervention_name>
    <description>Standard treatment of bladder/renal cancer according to the Clinical protocols</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Cytokine-induced killer cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of pTa metastatic tumors of the urogenital area;&#xD;
&#xD;
          -  Patient who require repetitive transurethral resection;&#xD;
&#xD;
          -  Expression of muc-1/wt-1 by the tumor;&#xD;
&#xD;
          -  EGOC 0-3;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any medical condition which can be associated with the high risk for the patient;&#xD;
&#xD;
          -  pregnancy/lactation;&#xD;
&#xD;
          -  chronic infections, including hepatitis B/C, tuberculosis, HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Hancharou</last_name>
    <role>Study Director</role>
    <affiliation>the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Prokhorov, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Belarusian State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrei Hancharou, Dr</last_name>
    <phone>+375296248972</phone>
    <email>hancharou@ibp.org.by</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oksana Timohina</last_name>
    <phone>+375299649741</phone>
    <email>oksanabuschik@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</name>
      <address>
        <city>Minsk</city>
        <zip>220072</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder Cancer</keyword>
  <keyword>Renal Cancer</keyword>
  <keyword>CIK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

